Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. COGNIFUL’s residence is in Mallorca, Spain, not the United States. The provider examples illustrate different care settings rather than an independent ranking or a claim that all offer equivalent luxury accommodation. Confirm current scope, eligibility, and availability directly. [1] [2]

Drug addiction is not one condition with a universal detox protocol. Assessment should identify prescribed and nonprescribed substances, alcohol, patterns of use, physical symptoms, mental health, and previous treatment. It should also establish what support and practical stability exist at home. Treatment options differ according to those findings, including whether outpatient or residential care is appropriate. [3]

Tell clinicians about the actual products and medication used, including uncertainty. A broad label such as party drugs or prescription dependence may conceal information needed for a safe plan. If medication was prescribed for an ongoing condition, include that history and the current prescriber. The goal is an accurate assessment, not a version of the history designed to secure admission.

Breathing difficulty, seizures, severe chest pain, acute confusion, or an immediate psychiatric crisis require urgent medical attention. Do not delay acute care while organizing a private stay or international travel. A residence’s ability to provide later therapy does not establish hospital-level capacity for intoxication, severe withdrawal, or acute psychiatric complications. [4] [5] [6]

Opioid use disorder

The CDC recommends offering or arranging evidence-based medication treatment for opioid use disorder. Detoxification alone without medication is not recommended because of increased risks of return to use and overdose. Ask every shortlisted provider who delivers the medication pathway, what monitoring is involved, and how it continues across changes in setting. A comfortable residence is not a substitute for that clinical responsibility. [7]

If medication treatment is already underway, involve the current prescriber before considering a new program. Ask whether the receiving team can maintain appropriate care and who will continue it after discharge. An overseas stay should not create an avoidable gap simply because a provider uses a general drug-free message. The decision belongs with the relevant qualified professionals.

Cocaine and other stimulants

The ASAM/AAAP guideline identifies contingency management as a primary component of stimulant use disorder treatment alongside other psychosocial work. This is a structured method for reinforcing agreed treatment behaviors. Ask whether it is available and how it is implemented. Cognitive behavioral and other approaches should also be described as actual proposed work rather than an unselected list of therapies. [5]

Ask how physical and psychiatric symptoms are monitored. Sleep, mood, anxiety, and other needs may continue after acute effects have passed. The team should explain when the current setting is sufficient and what would trigger further medical or psychiatric assessment. [5]

Benzodiazepines and other prescription concerns

Benzodiazepine physical dependence can develop during prescribed use. The assessment should distinguish that from other patterns of problematic use and preserve attention to the condition being treated. The FDA warns that abrupt discontinuation or rapid reduction can cause serious withdrawal. Do not change medication to fit a booking or a fixed residential timetable. [4]

Ask who will oversee any proposed medication review and what happens if the clinical process continues beyond discharge. The treatment plan should identify the ongoing prescriber and monitoring arrangements. The end of a purchased stay is not, by itself, a reason to end medical care.

Cannabis use disorder

The CDC describes relevant features such as loss of control, craving, unsuccessful attempts to reduce use, and effects on responsibilities or relationships. These require an individual assessment rather than a decision based only on legal availability or product labeling. Ask about psychological treatment and whether the home setting can support it. [8]

WHO guidance identifies cognitive behavioral, motivational enhancement, and family approaches as options for cannabis dependence, while giving the recommendation a conditional rating with low-quality evidence. A provider should explain its proposed approach without turning this into a guarantee or assuming that every cannabis concern calls for residential treatment. [9]

This is a small set of documented examples, not a national directory. UCLA is an outpatient comparison, while Betty Ford Center’s cited location is Rancho Mirage rather than Los Angeles or Malibu. COGNIFUL is overseas. These distinctions affect attendance, family involvement, travel, and how the next stage of treatment is arranged.

Ask why the proposed level of care fits your circumstances. Residential treatment may provide structure when appropriate, while outpatient care may allow treatment within ordinary life. The recommendation should account for symptoms, engagement, environment, and support. Choosing a less intensive setting when suitable is not a sign of lesser commitment. [3]

Request a schedule separating individual clinical work, medical review, shared activities, and other services. Ask which professionals coordinate decisions when substance use and mental health needs overlap. A comprehensive-looking list does not show how those elements become a coherent plan for the person receiving care.

Find out how progress is reviewed. Which goals are agreed, what information is used, and how does the team adjust treatment when needed? A completed stay or a full schedule does not establish a particular outcome. Be cautious about percentages that omit definitions, follow-up periods, or which patients were included.

Ask how the program responds when a need exceeds its scope. Who arranges additional assessment or transfer, how is the patient involved, and what information moves to the next service? A clear boundary is part of a usable proposal. A promise that every complication can be managed within one setting is not a substitute for those arrangements.

Discuss the person’s involvement in decisions when family, an employer, or an adviser is paying. Clarify consent and what administrative or clinical information each person may receive. Financial logistics should not obscure the patient’s understanding of the proposed care or their role in planning it.

COGNIFUL is part of THE BALANCE GROUP and offers private residential treatment in Mallorca. Its named addiction pathways include alcohol, cocaine, prescription drugs, and cannabis. Admission depends on clinical suitability and availability, with other medical or psychiatric care required first when appropriate. Those published pathways do not establish every opioid medication, detox, or acute hospital capability. [1] [6]

At any time, a maximum of four clients share the residence, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, and personal manager are shared in both programs. Other holistic sessions, excursions, and activities are shared in Premier; every session and activity is individual in Premier Plus. Both tiers use this format. The capacity does not establish a staffing ratio, continuous onsite physician coverage, or superior clinical outcomes. [2]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan, and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Further base-program follow-up is agreed individually. Typical stays are described as four to twelve weeks, with individual review. [12] [13] View program fees

Request the actual clinical plan before judging the residential experience. Ask which methods, clinicians, and reviews are proposed for the identified substances and symptoms. THE BALANCE GROUP’s shared team does not mean every professional participates in every admission. Nor does a guideline’s recommendation establish that every method or medication pathway is available at COGNIFUL. Confirm the relevant services explicitly. [14] [15]

COGNIFUL is self-pay and does not directly bill insurers; US reimbursement is not guaranteed. Ask for a written total with duration assumptions, inclusions, and exclusions. Continuing care should be discussed for the actual state of residence, including receiving clinicians and prescribing responsibilities. Plus aftercare is not a claim of unrestricted US telehealth or a replacement for all local care. [12] [13]

Identify a receiving US clinician or service before travel when possible. With consent, agree what records will be shared and who will send the discharge summary. Ask whether the receiving team can review the proposed plan in advance, especially when ongoing medication or monitoring is involved. COGNIFUL’s referral process supports discussing that coordination. [16]

Plan the first appointments after discharge around real work and family obligations. Clarify what can be provided remotely, at what times, and by whom. A video connection is not evidence that the same clinical service can be delivered in every jurisdiction. Local responsibilities should remain explicit.

Ask domestic providers directly about payment arrangements and coverage under the actual insurance policy. This guide does not establish insurance participation or benefits for a particular program. For an overseas stay, use the current written euro proposal and include known travel, external care, and follow-up costs in the comparison.

Review the first week at home with the treating team. Who can help if symptoms worsen? Which situations need a practical plan? What happens if substance use recurs? Continuing care should make reassessment and appropriate help easier to access, not rely on the assumption that an expensive stay prevents every future difficulty.

Ask how the proposed plan accounts for previous treatment. If an earlier episode helped in some ways but did not provide lasting support, identify what was useful and what was missing. A new program should be able to explain how that history informs assessment and planning. Repeating a familiar package in a more exclusive setting is not, by itself, a clinical explanation of what will be different.

Keep confirmed services separate from possibilities awaiting assessment. That simple distinction helps families compare proposals fairly and avoids treating an introductory conversation as a final commitment about treatment, availability, or cost.

Is detox alone enough for drug addiction?

No universal pathway applies, and stabilization is different from ongoing treatment. For opioid use disorder, the CDC advises against detoxification alone without medication because of the associated return-to-use and overdose risks. [7]

Does COGNIFUL operate in the United States?

The verified residence is in Mallorca, Spain. US residents need an overseas care plan with clinical acceptance, appropriate travel arrangements, and a receiving service at home. [2] [17]

Can one provider manage all substances and mental health needs?

Do not assume so. Ask about the actual substances, symptoms, medication requirements, and medical capacity. COGNIFUL may require another service to address some needs before residential admission. [6]

How do I explore a COGNIFUL stay?

Request a suitability review and provide accurate clinical information. Ask for the substance-specific plan, written fees, and US continuing-care arrangements before booking travel. Coordinate with existing clinicians with consent where helpful. [16] [12]

1. Addiction treatment at COGNIFUL — COGNIFUL
2. Life at COGNIFUL in Mallorca — COGNIFUL
3. Drug addiction: getting help — NHS
4. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — US Food and Drug Administration
5. ASAM/AAAP clinical practice guideline on the management of stimulant use disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry
6. Clinical scope, suitability and care coordination — COGNIFUL
7. Opioid use disorder: treating — Centers for Disease Control and Prevention
8. Understanding your risk for cannabis use disorder — Centers for Disease Control and Prevention
9. Psychosocial interventions for cannabis dependence — World Health Organization
10. Addiction Psychiatry Clinic — UCLA Health
11. Betty Ford Center in Rancho Mirage, California — Hazelden Betty Ford Foundation
12. COGNIFUL programs, fees and admissions — COGNIFUL
13. Reintegration and continuing care — COGNIFUL
14. Clinical team and care coordination — COGNIFUL
15. How residential treatment works at COGNIFUL — COGNIFUL
16. Professional referrals — COGNIFUL
17. Considering residential treatment in Mallorca: what to check before traveling — COGNIFUL

Source information checked October 18, 2026. Confirm current services, eligibility, fees, and availability directly with each provider.